PRISM hepatitis B surface antigen detection of hepatits B virus minipool nucleic acid testing yield samples

Transfusion

Volumn 48, Issue 7, 2008, Pages 1376-1382

  Linauts, Sandy ^a   Saldanha, John ^a   Strong, D Michael ^a  

^a PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ANTIGEN DETECTION; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; NUCLEIC ACID ANALYSIS; SCREENING TEST; VIRUS LOAD; BLOOD; CHEMISTRY; DNA SEQUENCE; GENETICS; HEPATITIS B; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY; VIROLOGY;

BLOOD DONORS; DNA, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 52049100624     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01698.x     Document Type: Article

References (34)

1. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91:1-12.
2. Stramer SL. Pooled HBV DNA testing by nucleic acid amplification: implementation or not. Transfusion 2005;42:1242-6.
3. Dodd RY, NotariI EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
4. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins CR, Chiaccherrini RP, Pietrelli LA. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005;45:1247-57.
5. Kleinman S, Busch M. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006;36:S23-S29.
6. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HbsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
7. ROCHE: COBAS® AmpliScreen HBV Test product insert: P/N 03599779 190. Indianapolis (IN): Roche Diagnostics;2007.
8. ROCHE: cobas TaqScreen MPX Test product insert: P/N 04584244 190. Roche Diagnostics GmbH D-68298 Mannheim (CE); 2007.
9. AUSZYME® monoclonal: antibody to hepatitis B surface antigen (mouse monoclonal): peroxides (horseradish) conjugate. List No. 1980; 34-3928/R15. Abbott Park (IL):AUSZYME® Monoclonal; 2005.
10. ORTHO®: ORTHO Antibody to HBsAg ELISA Test System 2. 631-20-086-6. Raritan (NJ): Ortho-Clinical Diagnostics; 2003.
11. ORTHO®: antibody to hepatitis B surface antigen (murine monoclonal): peroxidase conjugate ORTHO® antibody to HBsAg ELISA Test System 3. 631-20-086-6. Raritan (NJ): Ortho-Clinical Diagnostics; 2003.
12. PRISM®: antibody to hepatitis B surface antigen (mouse monoclonal IgM). List No. 6D19; 34-4212/R8 2006. Abbott Park (IL): Abbott PRISM; 2006.
13. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
14. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-73.
15. Sanchez LV, Maldonado M, Bastidas-Ramírez BE, Norder H, Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. J Gen Virol 2002;68:24-32.
16. FDA HHS CBER, Guidance for Industry. Adequate and appropriate donor screening tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) assays used to test donors of whole blood and blood components, including source plasma and source leukocytes. July 2007. [cited 20 Sep 2007]. Available from: http://www.fda.gov/cber/guidelines.htm
17. Minegishi K, Yoshikawa A, Kishimoto S, Yugi H, Yokoya N, Sakurada M, Kiyokawa H, Nishioka K & the Japanese Red Cross NA Screening Research Group. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescense immunoassay for hepatitis B surface antigen screening. Vox Sang 2003;84:287-91.
18. Allain J-P. International collaborative study proposal for the characterization of occult hepatitis B virus infection identified by nucleic acid or anti-HBc screening. Vox Sang 2007;92:254-7.
19. Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006;78:S66-S70.
20. Baginski I, Chemin I, Hantz O, Pichoud C, Jullien AM, Chevre JC, Vitvitski LL, Sninsky JJ, Trepo C. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion 1992;32:215-20.
21. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, Tsutsumi T, Kimura S, Koike K. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998;27:1377-82.
22. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kane-mitsu K, Nishioka K. Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005;88:77-86.
23. Weusten JJ, van Drimmelen AJ, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transfusion by window-phase donations not detected by NAT. Transfusion 2002;42:537-48.
24. Busch MP, Stramer SL, Strong DM, Hewlett IK, Epstein JS. International Forum: implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update through 2003. Response from the United States. Vox Sang 2005;88:298-301.
25. Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, Ohnuma H, Miyakawa K, Tachibana K, Mizoguchi H. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007;47:1162-71.
26. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002;42:1230-7.
27. Prince M, Lee D-H, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001;41:329-32.
28. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001;41:878-84.
29. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grünelt E, Nübling CM. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006;44:99-107.
30. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47:1197-205.
31. McMahon B, Bruden D, Petersen K. Antibody levels and protection after hepatitis B vaccination: results of a 15 year follow up. Ann Inter Med 2005;142:333-41.
32. Chen D. Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years. Ann Intern Med 2005;142:384-5.
33. Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006;44:39-46.
34. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.